MX345650B - Composicion que comprende 2-metilpropanotioato de s- [2 -( [ [1-(2-etilbutil) -ciclohexil] -carbonil]amino) fenil] y croscarmelosa de sodio. - Google Patents

Composicion que comprende 2-metilpropanotioato de s- [2 -( [ [1-(2-etilbutil) -ciclohexil] -carbonil]amino) fenil] y croscarmelosa de sodio.

Info

Publication number
MX345650B
MX345650B MX2013004584A MX2013004584A MX345650B MX 345650 B MX345650 B MX 345650B MX 2013004584 A MX2013004584 A MX 2013004584A MX 2013004584 A MX2013004584 A MX 2013004584A MX 345650 B MX345650 B MX 345650B
Authority
MX
Mexico
Prior art keywords
ethylbutyl
cyclohexyl
phenyl
amino
composition
Prior art date
Application number
MX2013004584A
Other languages
English (en)
Other versions
MX2013004584A (es
Inventor
Meyer Bernard
Krabichler Michaela
Winzenburg Carsten
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43759428&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX345650(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2013004584A publication Critical patent/MX2013004584A/es
Publication of MX345650B publication Critical patent/MX345650B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se relaciona a una composición que comprende: a) 2-metilpropanotioato de S-[2-([(1-(2-etilbutil)-cicl ohexil]-carbonil]amino)fenilo] y b) croscarmelosa de sodio. La presente invención también se relaciona con un proceso para la preparación de una composición que comprende los siguientes pasos: a) mezclar y granular el 2-metilpropanotioato de S-[2-([[1-(2-etilbutil)-ciclohexil]-carbonil] amino)fenilo], crospovidona, celulosa microcristalina, croscarmelosa de sodio e hidroxipropilmetilcelulosa; b) pulverizar hasta el 0.5 en peso de HPMC en agua o en 10%-30% de etanol en peso/70%-90% de agua en peso, sobre los gránulos obtenidos en el paso a); c) secar el granulado; y d) mezclar la celulosa microcristalina, dióxido de silicio coloidal y estearilfumarato de sodio con el granulad seco obtenido en el paso c).
MX2013004584A 2010-11-04 2011-10-31 Composicion que comprende 2-metilpropanotioato de s- [2 -( [ [1-(2-etilbutil) -ciclohexil] -carbonil]amino) fenil] y croscarmelosa de sodio. MX345650B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10190045 2010-11-04
PCT/EP2011/069087 WO2012059447A1 (en) 2010-11-04 2011-10-31 A composition comprising s-[2-([[1-(2-ethylbutyl)-cyclohexyl]-carbonyl]amino)phenyl]2-methylpropanethioate and croscarmellose sodium

Publications (2)

Publication Number Publication Date
MX2013004584A MX2013004584A (es) 2013-05-17
MX345650B true MX345650B (es) 2017-02-09

Family

ID=43759428

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013004584A MX345650B (es) 2010-11-04 2011-10-31 Composicion que comprende 2-metilpropanotioato de s- [2 -( [ [1-(2-etilbutil) -ciclohexil] -carbonil]amino) fenil] y croscarmelosa de sodio.

Country Status (24)

Country Link
US (1) US9107836B2 (es)
EP (1) EP2635263B1 (es)
JP (1) JP5676005B2 (es)
KR (1) KR101579659B1 (es)
CN (2) CN105833283A (es)
AR (1) AR083693A1 (es)
BR (1) BR112013010704B8 (es)
CA (1) CA2815280C (es)
CL (1) CL2013001164A1 (es)
CR (1) CR20130181A (es)
EA (1) EA025649B1 (es)
EC (1) ECSP13012603A (es)
ES (1) ES2553279T3 (es)
IL (1) IL225780B (es)
MA (1) MA34643B1 (es)
MX (1) MX345650B (es)
MY (1) MY164729A (es)
NZ (1) NZ609529A (es)
PE (1) PE20140018A1 (es)
SG (1) SG190025A1 (es)
TW (1) TWI507192B (es)
UA (1) UA110117C2 (es)
WO (1) WO2012059447A1 (es)
ZA (1) ZA201302954B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ594395A (en) 2009-02-10 2014-01-31 Amarin Pharmaceuticals Ie Ltd Use of eicosapentaenoic acid ethyl ester for treating hypertriglyceridemia
PT2978859T (pt) 2013-03-27 2018-10-04 Hoffmann La Roche Marcadores genéticos para previsão da capacidade de resposta à terapêutica
JP5871984B2 (ja) * 2013-04-15 2016-03-01 株式会社三和化学研究所 オルメサルタンメドキソミルを含有する医薬組成物
KR20160093024A (ko) 2013-12-19 2016-08-05 에프. 호프만-라 로슈 아게 눈 질환의 치료에 사용하기 위한 cetp 조절제
RU2703192C2 (ru) 2014-07-30 2019-10-15 Ф. Хоффманн-Ля Рош Аг Генетические маркеры для прогнозирования ответа на терапию поднимающими уровень hdl или имитирующими hdl агентами
CN104434913A (zh) * 2014-12-20 2015-03-25 长沙佰顺生物科技有限公司 一种安塞曲匹药物组合物及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2894445B2 (ja) 1997-02-12 1999-05-24 日本たばこ産業株式会社 Ｃｅｔｐ活性阻害剤として有効な化合物
US7208465B2 (en) * 2000-11-03 2007-04-24 The Procter & Gamble Company Methods and compositions for improved fragrancing of a surface
BR0317593A (pt) * 2002-12-20 2005-11-22 Pfizer Prod Inc Formas de dosagem compreendendo um inibidor de cetp e um inibidor de hmg-coa reductase
EP2289507A1 (en) 2003-03-17 2011-03-02 Japan Tobacco, Inc. Pharmaceutical compositions of CETP inhibitors
MXPA05009976A (es) 2003-03-17 2005-11-04 Japan Tobacco Inc Metodo para incrementar la biodisponibilidad oral del 2-metilpropantioato de s-[2-([[1- 2-etilbutil) ciclohexil] carbonil] amino) fenilo].
MXPA06001506A (es) * 2003-08-04 2006-05-15 Pfizer Prod Inc Formas de dosificacion de inhibidores de la proteina de transferencia de colesteril ester e inhibidores de la hmg-coa reductasa.
DE602006004558D1 (de) * 2005-01-28 2009-02-12 Pfizer Prod Inc Schnell zerfallendes mikroporöses bindemittel und herstellungsverfahren dafür
US7435849B2 (en) 2005-10-31 2008-10-14 Hoffmann-La Roche Inc. Process for the production of acid chlorides
EP1935867A1 (en) 2006-12-20 2008-06-25 F. Hoffmann-La Roche Ag Process for preparing 1-(2-ethyl-butyl)-cyclohexanecarboxylic acid
BRPI0922888A2 (pt) * 2008-12-08 2019-09-24 Hoffmann La Roche administração combinada de fármaco
US20110004011A1 (en) 2009-07-01 2011-01-06 Declan Costello Novel process

Also Published As

Publication number Publication date
EA025649B1 (ru) 2017-01-30
KR20130083922A (ko) 2013-07-23
BR112013010704A2 (pt) 2016-08-09
UA110117C2 (uk) 2015-11-25
CA2815280A1 (en) 2012-05-10
AR083693A1 (es) 2013-03-13
MA34643B1 (fr) 2013-11-02
BR112013010704B8 (pt) 2021-11-09
AU2011325235A8 (en) 2016-02-04
US20120115946A1 (en) 2012-05-10
EP2635263A1 (en) 2013-09-11
US9107836B2 (en) 2015-08-18
CA2815280C (en) 2016-08-09
ES2553279T3 (es) 2015-12-07
EA201390622A1 (ru) 2013-10-30
KR101579659B1 (ko) 2015-12-22
BR112013010704B1 (pt) 2021-06-29
PE20140018A1 (es) 2014-01-31
SG190025A1 (en) 2013-06-28
CL2013001164A1 (es) 2013-12-27
JP5676005B2 (ja) 2015-02-25
CN105833283A (zh) 2016-08-10
EP2635263B1 (en) 2015-09-23
JP2013541572A (ja) 2013-11-14
IL225780B (en) 2018-10-31
AU2011325235A1 (en) 2013-05-02
ECSP13012603A (es) 2013-07-31
WO2012059447A1 (en) 2012-05-10
IL225780A0 (en) 2013-06-27
MX2013004584A (es) 2013-05-17
CR20130181A (es) 2013-05-29
ZA201302954B (en) 2016-01-27
AU2011325235B2 (en) 2016-01-21
MY164729A (en) 2018-01-30
CN103200935A (zh) 2013-07-10
TWI507192B (zh) 2015-11-11
NZ609529A (en) 2015-06-26
TW201300104A (zh) 2013-01-01

Similar Documents

Publication Publication Date Title
MX345650B (es) Composicion que comprende 2-metilpropanotioato de s- [2 -( [ [1-(2-etilbutil) -ciclohexil] -carbonil]amino) fenil] y croscarmelosa de sodio.
CY1124874T1 (el) Διεργασια για την παρασκευη [(5-(3-χλωροφαινυλ)-3-υδροξυπυριδινο-2-καρβονυλ)-αμινο]οξικου οξεος απο 5-((3-χλωροφαινυλ)-3-χλωρο-πυριδιν-2-υλ)-νιτριλιο, και διεργασια για την παρασκευη παραγωγων 5-((αλογονοφαινυλ)-3-αλογονο-πυριδιν-2-υλ)-νιτριλιου
WO2012147107A3 (en) Novel & improved processes for preparing indoline derivatives and its pharmaceutical composition
UA104590C2 (ru) Капсулированная лекарственная форма, содержащая суспензионную композицию производной индолинона
TW200643013A (en) Pyrazoles
NZ600210A (en) Substituted 4-aminocyclohexane derivatives
ATE551328T1 (de) Neuartige 5-substituierte hydantoine
MX2009006865A (es) Proceso para la preparacion de compuestos 6,6-dimetil-3-aza-bicicl o-[3.1.0]-hexano utilizando intermediario bisulfitico.
JO2973B1 (en) Fumarate salt for (alpha-beta-R) -6-bromo-alpha-[2- (methylamino) ethyl-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinoline ethanol
MX343837B (es) Derivados de 2 - (1,2,3 -triazol - 2 - il) benzamida y 3 - (1,2,3 - triazol - 2 - il) picolinamida.
NZ599254A (en) Novel vanilloid receptor ligands and the use thereof for the production of pharmaceuticals
MX2012005329A (es) Compuestos benzoimidazolicos y sus usos.
EA200900707A1 (ru) Новый способ синтеза 7,8-диметокси-1,3-дигидро-2h-3-бензазепин-2-она, и его применение при синтезе ивабрадина и его солей присоединения с фармацевтически приемлемой кислотой
ATE399156T1 (de) Neue indol- oder benzimidazol-derivate
JO2749B1 (en) Indole-2-Wen derivatives bilaterally substituted at position 3, their preparation and therapeutic application
WO2012161497A3 (ko) 보습능이 우수한 펩타이드 유도체 및 이의 용도
WO2010041277A3 (en) Stable pharmaceutical compositions of montelukast or its salts or solvates or hydrates
RU2014119866A (ru) Твердые дозированные формы (s)-этил 2-амино-3-(2-амино-6(r)-1-(4-хлор-2-(3-метил-1н-пиразол-1-ил)фенил)-2,2,2-трифторэтокси)пиримидин-4-ил)фенил)пропаноата
WO2011084434A3 (en) Aza-ring fused indole and indoline derivatives
MX2012007927A (es) Antagonistas de dp2 y usos del mismo.
MX2013006031A (es) Formulacion liposomal de dalcetrapib.
NZ619257A (en) Ketamine derivatives
NZ609596A (en) Cyclohexane derivative compound
JP2010527364A5 (es)
WO2008099781A1 (ja) アミノアルコール誘導体を有効成分とする脱髄性疾患の治療剤又は予防剤

Legal Events

Date Code Title Description
FG Grant or registration